Northern Trust’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$466M Sell
5,824,369
-56,119
-1% -$4.63M 0.06% 268
2025
Q4
$501M Sell
5,880,488
-160,157
-3% -$13.1M 0.06% 254
2025
Q3
$470M Sell
6,040,645
-70,882
-1% -$5.54M 0.06% 273
2025
Q2
$478M Sell
6,111,527
-136,690
-2% -$10.2M 0.07% 259
2025
Q1
$453M Sell
6,248,217
-257,010
-4% -$18.4M 0.07% 267
2024
Q4
$482M Buy
6,505,227
+1,165,845
+22% +$81.6M 0.07% 247
2024
Q3
$352M Sell
5,339,382
-376,879
-7% -$27.4M 0.06% 292
2024
Q2
$528M Sell
5,716,261
-49,100
-0.9% -$4.35M 0.09% 201
2024
Q1
$551M Sell
5,765,361
-186,889
-3% -$15.7M 0.1% 203
2023
Q4
$454M Sell
5,952,250
-405,223
-6% -$28.2M 0.08% 226
2023
Q3
$440M Buy
6,357,473
+241,347
+4% +$19.4M 0.09% 216
2023
Q2
$577M Sell
6,116,126
-434,642
-7% -$37.8M 0.11% 169
2023
Q1
$542M Buy
6,550,768
+16,469
+0.3% +$1.29M 0.11% 184
2022
Q4
$488M Buy
6,534,299
+34,664
+0.5% +$2.67M 0.1% 198
2022
Q3
$537M Sell
6,499,635
-89,395
-1% -$8.6M 0.12% 159
2022
Q2
$627M Sell
6,589,030
-152,687
-2% -$15.8M 0.13% 148
2022
Q1
$794M Sell
6,741,717
-37,218
-0.5% -$4.18M 0.14% 138
2021
Q4
$878M Buy
6,778,935
+12,042
+0.2% +$1.4M 0.14% 130
2021
Q3
$766M Buy
6,766,893
+75,851
+1% +$8.66M 0.14% 133
2021
Q2
$693M Sell
6,691,042
-95,426
-1% -$8.99M 0.12% 151
2021
Q1
$568M Sell
6,786,468
-1,820
-0% -$154K 0.11% 173
2020
Q4
$619M Sell
6,788,288
-270,042
-4% -$22.4M 0.12% 153
2020
Q3
$563M Sell
7,058,330
-60,991
-0.9% -$4.76M 0.12% 157
2020
Q2
$492M Buy
7,119,321
+91,074
+1% +$6.47M 0.12% 161
2020
Q1
$442M Sell
7,028,247
-75,402
-1% -$5.44M 0.13% 157
2019
Q4
$552M Sell
7,103,649
-34,500
-0.5% -$2.69M 0.12% 159
2019
Q3
$523M Sell
7,138,149
-129,648
-2% -$9.11M 0.13% 163
2019
Q2
$448M Buy
7,267,797
+146,793
+2% +$8.88M 0.11% 190
2019
Q1
$454M Buy
7,121,004
+67,608
+1% +$3.86M 0.11% 180
2018
Q4
$360M Buy
7,053,396
+226,173
+3% +$11.4M 0.1% 195
2018
Q3
$396M Sell
6,827,223
-320,541
-4% -$15.7M 0.1% 201
2018
Q2
$347M Buy
7,147,764
+1,713
+0% +$80K 0.09% 218
2018
Q1
$332M Sell
7,146,051
-115,068
-2% -$5M 0.09% 230
2017
Q4
$273M Sell
7,261,119
-98,310
-1% -$3.61M 0.07% 274
2017
Q3
$268M Buy
7,359,429
+384,990
+6% +$14.7M 0.07% 275
2017
Q2
$275M Sell
6,974,439
-231,387
-3% -$8.45M 0.08% 251
2017
Q1
$226M Sell
7,205,826
-18,702
-0.3% -$586K 0.07% 292
2016
Q4
$226M Sell
7,224,528
-636,312
-8% -$20.6M 0.07% 280
2016
Q3
$316M Buy
7,860,840
+58,509
+0.7% +$2.2M 0.1% 206
2016
Q2
$259M Sell
7,802,331
-75,330
-1% -$2.58M 0.08% 243
2016
Q1
$246M Buy
7,877,661
+20,904
+0.3% +$577K 0.08% 246
2015
Q4
$207M Sell
7,856,757
-535,521
-6% -$13.9M 0.07% 281
2015
Q3
$199M Sell
8,392,278
-253,098
-3% -$6.11M 0.07% 287
2015
Q2
$205M Buy
8,645,376
+260,604
+3% +$5.88M 0.06% 305
2015
Q1
$199M Sell
8,384,772
-182,040
-2% -$4.08M 0.06% 317
2014
Q4
$182M Buy
8,566,812
+50,778
+0.6% +$1.02M 0.05% 335
2014
Q3
$145M Sell
8,516,034
-108,696
-1% -$1.72M 0.05% 370
2014
Q2
$123M Sell
8,624,730
-714,792
-8% -$9.69M 0.04% 424
2014
Q1
$115M Buy
9,339,522
+48,894
+0.5% +$564K 0.04% 442
2013
Q4
$102M Buy
9,290,628
+186,816
+2% +$2.11M 0.03% 462
2013
Q3
$106M Sell
9,103,812
-717,438
-7% -$8.39M 0.04% 424
2013
Q2
$110M Buy
+9,821,250
New +$116M 0.04% 403

Other funds holding EW

Northern Trust's EW Position: Q1 2026 in Review

Northern Trust reduced its Edwards Lifesciences (EW) stake by 0.95% in Q1 2026, selling an estimated $4.63M and leaving 5,824,369 shares worth $466M. The position accounts for 0.06% of the portfolio, ranked #268.

Northern Trust first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $878M in Q4 2021. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Northern Trust held 5,824,369 shares of Edwards Lifesciences worth $466M as of Q1 2026.
  • Northern Trust sold 56,119 Edwards Lifesciences shares in Q1 2026, an estimated $4.63M.
  • Edwards Lifesciences made up 0.06% of Northern Trust's portfolio in Q1 2026, its #268 holding.
  • Northern Trust first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Northern Trust's Edwards Lifesciences position peaked at $878M in Q4 2021.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.